Annexin A2 is not a good biomarker for hepatocellular carcinoma in cirrhosis

Liu,Zhikun; Ling,Qi; Wang,Jianguo; Xie,Haiyang; Xu,Xiao; Zheng,Shusen

doi:10.3892/ol.2013.1337

Annexin A2 is not a good biomarker for hepatocellular carcinoma in cirrhosis

Authors:
- Zhikun Liu
- Qi Ling
- Jianguo Wang
- Haiyang Xie
- Xiao Xu
- Shusen Zheng
View Affiliations

Affiliations: Key Laboratory of Combined Multi-Organ Transplantation, Ministry of Public Health, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, P.R. China, Department of Surgery, Division of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, P.R. China
Published online on: May 8, 2013 https://doi.org/10.3892/ol.2013.1337
Pages: 125-129

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In China, hepatocellular carcinoma (HCC) usually develops following a long history of chronic hepatitis B infection or cirrhosis. To evaluate the diagnostic role of annexin A2 (ANXA2), a possible tumor marker, in patients with hepatitis B virus (HBV)‑related HCC, particularly those with a history of cirrhosis, the present study prospectively enrolled 87 patients with HBV‑related HCC (with cirrhosis), 39 patients with HBV‑related cirrhosis and 27 healthy controls. The expression levels of serum and tissue ANXA2 were determined using an enzyme‑linked immunosorbent assay (ELISA) and immunohistochemical staining, respectively. The serum levels of ANXA2 were significantly elevated in the patients with HCC (median, 567.2 µg/ml; P=0.003) and cirrhosis (median, 414.8 µg/ml; P=0.011) compared with the healthy controls (median, 241.9 µg/ml). However, no significant differences were observed in the serum ANXA2 levels between the patients with HCC and those with cirrhosis. The immunohistochemical staining analysis showed that the healthy controls did not show positive staining, while the number of cases immunoreactive for ANXA2 steadily increased from the liver cirrhosis tissues (20/39, 51.3%) to the non‑cancer (53/87, 60.9%) and cancer tissues (68/87, 78.2%). The cancer tissues exhibited a significantly higher ANXA2‑positive rate compared with the non‑cancer (P=0.013) and liver cirrhosis tissues (P=0.002). Furthermore, marked ANXA2 staining was more prevalent in the cancer tissues (16/87, 18.4%) than the non‑cancer (4/87, 4.6%; P=0.004) and liver cirrhosis (1/39, 2.6%; P=0.034) tissues. The sensitivity, specificity and diagnostic accuracy of tissue ANXA2 for HCC in cirrhosis were 78.2, 42.1 and 56.8%, respectively. The ANXA2 expression levels in the serum and cancer tissues were not associated with tumor‑free survival or patient survival following liver transplantation. Serum or tissue ANXA2 is not a good diagnostic marker for HCC in HBV‑related cirrhosis and is not associated with prognosis.

View Figures

View References

1.	Gomaa AI, Khan SA, Toledano MB, Waked I and Taylor-Robinson SD: Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol. 14:4300–4308. 2008. View Article : Google Scholar : PubMed/NCBI
2.	Zhou L, Liu J and Luo F: Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol. 12:1175–1181. 2006.PubMed/NCBI
3.	Inagaki Y, Xu HL, Hasegawa K, et al: Des-gamma-carboxyprothrombin in patients with hepatocellular carcinoma and liver cirrhosis. J Dig Dis. 12:481–488. 2011. View Article : Google Scholar : PubMed/NCBI
4.	Liu J and Fan D: Hepatitis B in China. Lancet. 369:1582–1583. 2007. View Article : Google Scholar : PubMed/NCBI
5.	Fattovich G, Stroffolini T, Zagni I and Donato F: Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 127(5 Suppl 1): S35–S50. 2004. View Article : Google Scholar : PubMed/NCBI
6.	Fritz K, Fritz G, Windschiegl B, Steinem C and Nickel B: Arrangement of Annexin A2 tetramer and its impact on the structure and diffusivity of supported lipid bilayers. Soft Matter. 6:4084–4094. 2010. View Article : Google Scholar
7.	Mai J, Waisman DM and Sloane BF: Cell surface complex of cathepsin B/annexin II tetramer in malignant progression. Biochim Biophys Acta. 1477:215–230. 2000. View Article : Google Scholar : PubMed/NCBI
8.	Chiang Y, Rizzino A, Sibenaller ZA, Wold MS and Vishwanatha JK: Specific down-regulation of annexin II expression in human cells interferes with cell proliferation. Mol Cell Biochem. 199:139–147. 1999. View Article : Google Scholar : PubMed/NCBI
9.	Jacovina AT, Deora AB, Ling Q, et al: Homocysteine inhibits neoangiogenesis in mice through blockade of annexin A2-dependent fibrinolysis. J Clin Invest. 119:3384–3394. 2009.PubMed/NCBI
10.	Hajjar KA and Acharya SS: Annexin II and regulation of cell surface fibrinolysis. Ann NY Acad Sci. 902:265–271. 2000. View Article : Google Scholar : PubMed/NCBI
11.	Takahashi S, Reddy SV, Chirgwin JM, et al: Cloning and identification of annexin II as an autocrine/paracrine factor that increases osteoclast formation and bone resorption. J Biol Chem. 269:28696–28701. 1994.PubMed/NCBI
12.	Huang Y, Jin Y, Yan CH, et al: Involvement of Annexin A2 in p53 induced apoptosis in lung cancer. Mol Cell Biochem. 309:117–123. 2008. View Article : Google Scholar : PubMed/NCBI
13.	Bao H, Jiang M, Zhu M, Sheng F, Ruan J and Ruan C: Overexpression of Annexin II affects the proliferation, apoptosis, invasion and production of proangiogenic factors in multiple myeloma. Int J Hematol. 90:177–185. 2009. View Article : Google Scholar : PubMed/NCBI
14.	Sarkar S, Swiercz R, Kantara C, Hajjar KA and Singh P: Annexin A2 mediates up-regulation of NF-κB, β-catenin, and stem cell in response to progastrin in mice and HEK-293 cells. Gastroenterology. 140:583–595. e583–e595. 2011
15.	Ji NY, Park MY, Kang YH, et al: Evaluation of annexin II as a potential serum marker for hepatocellular carcinoma using a developed sandwich ELISA method. Int J Mol Med. 24:765–771. 2009.PubMed/NCBI
16.	Zhang L, Peng X, Zhang Z, et al: Subcellular proteome analysis unraveled annexin A2 related to immune liver fibrosis. J Cell Biochem. 110:219–228. 2010.PubMed/NCBI
17.	Lu AW, Zheng SS, Wu MP, Shen Y and Yang RW: Reevaluation of the effect of lamivudine therapy preoperative to prevent HBV recurrence after liver transplantation. Hepatobiliary Pancreat Dis Int. 7:357–361. 2008.PubMed/NCBI
18.	Zheng SS, Xu X, Wu J, et al: Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation. 85:1726–1732. 2008. View Article : Google Scholar : PubMed/NCBI
19.	Sun YL, Yin SY, Xie HY, et al: Stem-like cells in hepatitis B virus-associated cirrhotic livers and adjacent tissue to hepatocellular carcinomas possess the capacity of tumorigenicity. J Gastroenterol Hepatol. 23:1280–1286. 2008. View Article : Google Scholar : PubMed/NCBI
20.	Remmele W and Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 8:138–140. 1987.(In German).
21.	Ozkan G, Tutar M, Bayram M, et al: The impact of ultra-sonography-guided fine needle aspiration of no palpable supraclavicular lymph nodes on diagnosis and staging in advanced lung cancer. Tuberk Toraks. 57:186–191. 2009.PubMed/NCBI
22.	Zhang L, Jia X, Feng Y, et al: Plasma membrane proteome analysis of the early effect of alcohol on liver: implications for alcoholic liver disease. Acta Biochim Biophys Sin (Shanghai). 43:19–29. 2011. View Article : Google Scholar : PubMed/NCBI
23.	Seth D, Hogg PJ, Gorrell MD, McCaughan GW and Haber PS: Direct effects of alcohol on hepatic fibrinolytic balance: implications for alcoholic liver disease. J Hepatol. 48:614–627. 2008. View Article : Google Scholar : PubMed/NCBI
24.	Jia XF, Peng X, Feng YL, Yang H, Yuan ZH and Zhang LJ: Subcellular proteome analysis of immune or alcohol induced rat liver fibrosis. Zhonghua Gan Zang Bing Za Zhi. 18:826–830. 2010.(In Chinese).